A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Lingling ZHANG; Xiangyi WANG; Xing WEI; Li LIN; Chuanhao TANG; Jun LIANG

doi:10.19401/j.cnki.1007-3639.2023.08.006

您当前的位置：

首页 >

文章列表页 >

A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Article | 更新时间：2025-12-31

- A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis
- China Oncology Vol. 33, Issue 8, Pages: 776-781(2023)
- 作者机构：
  
  北京大学国际医院肿瘤内科，北京 102206
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.08.006
  CLC： R734.2
- Received：16 May 2023，
  
  Revised：2023-07-09，
  
  Published：30 August 2023
- 稿件说明：
移动端阅览
Lingling ZHANG, Xiangyi WANG, Xing WEI, et al. A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis[J]. China Oncology, 2023, 33(8): 776-781.
DOI：

Lingling ZHANG, Xiangyi WANG, Xing WEI, et al. A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis[J]. China Oncology, 2023, 33(8): 776-781. DOI： 10.19401/j.cnki.1007-3639.2023.08.006.

摘要

背景与目的：

晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）患者接受高致吐风险的含铂双药化疗，即使采用三联

或四联止吐方案，仍有相当一部分患者会出现化疗后恶心呕吐。止吐用低频电刺激仪是一种穿戴式电子止吐仪，可有效地降低各种原因引起的恶心呕吐反应，然而，在三联止吐药物的基础上联合止吐用低频电刺激仪是否可进一步提高化疗导致的恶心呕吐（chemotherapy-induced nausea and vomiting，CINV）的控制率，目前未见报道。本研究旨在评估止吐用低频电刺激仪辅助标准止吐药在应用高致吐化疗方案的NSCLC患者中的疗效和耐受性。

方法：

回顾性收集北京大学国际医院2019年12月1日—2022年12月30日接受一线高致吐化疗方案的晚期NSCLC患者，正确佩戴止吐用低频电刺激仪的患者作为观察组，未佩戴低频电刺激仪的化疗患者作为对照组。收集患者的临床特征、化疗后恶心呕吐发生情况，并进行患者化疗后的功能性生活指数-呕吐（functional living index-emesis，FLIE）问卷调查。采用SPSS 20.0进行统计学分析，比较两组间呕吐完全缓解率、恶心发生率和FLIE评分。

结果：

和对照组相比，试验组的全程无恶心率（66.3%

51.1%，

=0.036）和呕吐完全缓解率（83.7%

66.3%，

=0.006）显著提高；化疗后24~120 h的延迟期呕吐完全缓解率试验组显著提高（88.0%

69.6%，

=0.002），无恶心率显著提高（73.9%

57.6%，

=0.020）。试验组患者报告的FLIE总分和对照组患者相比差异有统计学意义（106.05±15.35

95.04±20.02，

=0.020）。

结论：

本研究结果提示，在三联止吐方案的基础上，佩戴止吐用低频电刺激仪可改善NSCLC患者CINV的控制水平并提高患者生活质量，可作为三联止吐方案的有效补充。

Abstract

Background and purpose:

In patients with advanced non-small cell lung cancer (NSCLC) who receive platinum-containing dual-drug chemotherapy with high emetic risk

a significant number of patients experience nausea and vomiting after chemotherapy

even if they are treated with a triple or quadruple antiemetic regimen. The low-frequency electrical stimulator for antiemesis is a wearable electronic antiemesis device

which can effectively reduce nausea and vomiting caused by various reasons. However

no studies have investigated whether the combination of three antiemetic drugs with low-frequency electrical stimulator can further improve the control rate of chemotherapy-induced nausea and vomiting (CINV). Therefore

the aim of this study was to assess the efficacy and tolerability of low-frequency electrical stimulator for antiemesis plus standard antiemetics following highly emetogenic chemotherapy in patients with NSCLC.

Methods:

Data of patients

with advanced NSCLC who received first-line hyperemetic chemotherapy at Peking University International Hospital from December 1

2019 to December 30

2022 were retrospectively collected. Patients who correctly wore low-frequency electrical stimulator for antiemesis were selected as the observation group

and chemotherapy patients who did not wear low-frequency electrical stimulator were selected as the control group. Clinical characteristics

occurrence of nausea and vomiting after chemotherapy and functional living index-emesis (FLIE) questionnaire were collected. SPSS 20.0 was used for statistical analysis to compare the vomiting complete response rate

nausea incidence and FLIE score between the two groups.

Results:

Compared with the control group

the no nausea rate (66.3%

51.1%

=0.036) and the complete response rate of vomiting (83.7%

66.3%

=0.006) in experimental group were significantly increased. At 24-120 h after chemotherapy

the complete response rate of vomiting at the delayed stage increased conspicuously in the observation group (88.0%

69.6%

=0.002). At this stage

the proportion of patients without nausea in the observation group was also significantly higher (73.9%

57.6%

=0.020). The total FLIE scores were conspicuously higher in the observation group than in the control group (106.05±15.35

95.04±20.02

=0.020).

Conclusion:

The results suggest that

on the basis of the triple antiemesis regimen

wearing the low-frequency electrical stimulator can significantly improve the control level of CINV and the quality of life of NSCLC patients

which can be an effective supplement to the triple antiemesis regimen.

关键词

Keywords

references

BARBOUR S Y . Management of patients with chemotherapy-induced nausea and vomiting [J ] . J Adv Pract Oncol , 2017 , 8 ( 3 ): 303 - 308 .

FARRELL C , BREARLEY S G , PILLING M , et al . The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life [J ] . Support Care Cancer , 2013 , 21 ( 1 ): 59 - 66 . DOI: 10.1007/s00520-012-1493-9 http://doi.org/10.1007/s00520-012-1493-9

AAPRO M . CINV: still troubling patients after all these years [J ] . Support Care Cancer , 2018 , 26 ( 1 ): 5 - 9 . DOI: 10.1007/s00520-018-4131-3 http://doi.org/10.1007/s00520-018-4131-3

RAZVI Y , CHAN S , MCFARLANE T , et al. ASCO , NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients [J ] . Support Care Cancer , 2019 , 27 ( 1 ): 87 - 95 . DOI: 10.1007/s00520-018-4464-y http://doi.org/10.1007/s00520-018-4464-y

GAO A , GUAN S , SUN Y , et al . Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy [J ] . BMC Cancer , 2023 , 23 ( 1 ): 609 . DOI: 10.1186/s12885-023-11070-3 http://doi.org/10.1186/s12885-023-11070-3

WEINSTEIN C , JORDAN K , GREEN S , et al . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type [J ] . BMC Cancer , 2020 , 20 ( 1 ): 918 . DOI: 10.1186/s12885-020-07259-5 http://doi.org/10.1186/s12885-020-07259-5

LOWN E A , BANERJEE A , VITTINGHOFF E , et al . Acupressure to reduce treatment-related symptoms for children with cancer and recipients of hematopoietic stem cell transplant: protocol for a randomized controlled trial [J ] . Glob Adv Health Med , 2019 , 8 : 2164956119870444.

WEBER B , KNOTH S , KRANKE P , et al . Study protocol for a randomised, patient- and observer-blinded evaluation of P6 acustimulation for the prevention of nausea and vomiting in the postoperative period in patients receiving routine pharmacological prophylaxis (P6NV-Trial) [J ] . Trials , 2022 , 23 ( 1 ): 497 . DOI: 10.1186/s13063-022-06369-8 http://doi.org/10.1186/s13063-022-06369-8

Reliefb and technologies [EB/OL ] . [2023-04-20] http://www.reliefband.com. http://www.reliefband.com. http://www.reliefband.com.

ALHAMMAD A M , ALKHUDAIR N , ALZAIDI R , et al . Assessing the impact of chemotherapy-induced nausea and vomiting on patients' quality of life: an Arabic version of the functional living index-emesis [J ] . J Oncol Pharm Pract , 2022 , 28 ( 3 ): 535 - 541 . DOI: 10.1177/1078155221998447 http://doi.org/10.1177/1078155221998447 http://journals.sagepub.com/doi/10.1177/1078155221998447 http://journals.sagepub.com/doi/10.1177/1078155221998447

PONS-TOSTIVINT E , BENNOUNA J . Treatments for non-small cell lung cancer: the multiple options for precision medicine [J ] . Curr Oncol , 2022 , 29 ( 10 ): 7106 - 7108 . DOI: 10.3390/curroncol29100558 http://doi.org/10.3390/curroncol29100558 https://www.mdpi.com/1718-7729/29/10/558 https://www.mdpi.com/1718-7729/29/10/558

HERBST R S , MORGENSZTERN D , BOSHOFF C . The biology and management of non-small cell lung cancer [J ] . Nature , 2018 , 553 ( 7689 ): 446 - 454 . DOI: 10.1038/nature25183 http://doi.org/10.1038/nature25183

GUPTA K , WALTON R , KATARIA S P . Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends [J ] . Cancer Treat Res Commun , 2021 , 26 : 100278 .

PIECHOTTA V , ADAMS A , HAQUE M , et al . Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis [J ] . Cochrane Database Syst Rev , 2021 , 11 ( 11 ): CD012775.

ZHAO Y Z , DAI Y Z , NIE K . Research progress on the antiemetic effect of traditional Chinese medicine against chemotherapy-induced nausea and vomiting: a review [J ] . Front Pharmacol , 2021 , 12 : 790784 . DOI: 10.3389/fphar.2021.790784 http://doi.org/10.3389/fphar.2021.790784 https://www.frontiersin.org/articles/10.3389/fphar.2021.790784/full https://www.frontiersin.org/articles/10.3389/fphar.2021.790784/full

CHEN M H , MAY B H , ZHOU I W , et al . Integrative medicine for relief of nausea and vomiting in the treatment of colorectal cancer using oxaliplatin-based chemotherapy: a systematic review and meta-analysis [J ] . Phytother Res , 2016 , 30 ( 5 ): 741 - 753 . DOI: 10.1002/ptr.5586 http://doi.org/10.1002/ptr.5586

CHEN B , GUO Y , ZHAO X , et al . Efficacy differences of electroacupuncture with single acupoint or matching acupoints for chemotherapy-induced nausea and vomiting: study protocol for a randomized controlled trial [J ] . Trials , 2017 , 18 ( 1 ): 477 . DOI: 10.1186/s13063-017-2186-y http://doi.org/10.1186/s13063-017-2186-y

GARCIA G T , RIBEIRO R F , FARIA SANTOS I B , et al . Electrical stimulation of PC 6 to control chemotherapy-induced nausea and vomiting in patients with cancer: a systematic review and meta-analysis [J ] . Med Acupunct , 2021 , 33 ( 1 ): 22 - 44 . DOI: 10.1089/acu.2020.1431 http://doi.org/10.1089/acu.2020.1431

Views

2590

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

BIMcombined with Scribble predicts treatment effect from chemotherapy in advanced non-small cell lung cancer

Relationship between MTHFR C677T gene polymorphisms and chemotherapy side effects in advanced non-small cell lung cancer

Efficacy of EGFR-TKI and chemotherapy in advanced non-small cell lung cancer with EGFR-TKI resistence

Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Related Author

张龙富

姚家美

蒋冬先

侯英勇

张　新

寇军燕

洪卫

洪丹

Related Institution

上海市徐汇区中心医院呼吸科

复旦大学附属中山医院呼吸科

复旦大学附属中山医院病理科

杭州市肿瘤医院肿瘤综合科

浙江省肿瘤医院化疗中心十六病区

AI问答

⁰